Sodium intake associated with increased lightheadedness in context of DASH-sodium trial
Study turns common knowledge on its head by challenging experts’ traditional recommendations
BOSTON – Lightheadedness with standing, otherwise known as postural lightheadedness, results from a gravitational drop in blood pressure and is common among adults. While mild in many adults, it has been cited as an important contributing factor in some harmful clinical events, such as falls. As a result, greater sodium intake is widely viewed as an intervention for preventing lightheadedness when moving from seated to standing positions.
However, contrary to this recommendation, researchers at Beth Israel Deaconess Medical Center (BIDMC) found that higher sodium intake, when studied in the context of the DASH-Sodium trial (Dietary Approaches to Stop Hypertension), actually increases lightheadedness. These findings challenge traditional recommendations to increase sodium intake to prevent lightheadedness. The study appeared today in the Journal of Clinical Hypertension.
“Our study has real clinical and research implications,” said Stephen Juraschek, MD, PhD, the study’s corresponding author and a primary care physician at BIDMC. “Our results serve to caution health practitioners against recommending increased sodium intake as a universal treatment for lightheadedness. Additionally, our results demonstrate the need for additional research to understand the role of sodium, and more broadly of diet, on lightheadedness.”
The researchers used data from the completed DASH-Sodium trial, a randomized crossover study that looked at the effects of three different sodium levels (1500, 2300, and 3300 mg/d) on blood pressure. All participants ate each of the three sodium levels in random order for four weeks. Half of the participants ate the sodium levels in the context of a typical American diet (a control diet) while the other half ate the sodium levels consistent with DASH diet guidelines. The original trial showed that by lowering sodium, blood pressure was also lowered – and was the basis for current guidelines for sodium consumption. The study also asked people to rate their experience of lightheadedness when they stood up, although these data were never reported. As such, in this secondary analysis of the DASH-Sodium trial, the researchers examined the impact of increased sodium intake on postural lightheadedness.
The study’s findings suggest that concerns about reducing sodium causing lightheadedness may not be scientifically based. It also further questions recommendations to use sodium to treat lightheadedness, an intervention that could have negative effects on cardiovascular health.
“Health practitioners initiating sodium interventions for orthostatic symptoms now have some evidence that sodium might actually worsen symptoms,” said Juraschek. “Clinicians should check on symptoms after initiation and even question the utility of this approach. More importantly, research is needed to understand the effects of sodium on physical function, particularly in older adults.”
The study also examined subgroups of the population, including older adults (age 60 and above) and adults with obesity. The effects of sodium on lightheadedness differed between these groups. In particular, higher sodium increased lightheadedness in younger people, but modestly reduced lightheadedness in older adults.
“Sodium is widespread in our foods, yet its effects are poorly understood,” said Juraschek. “This study illustrates the importance of more trials involving the foods we eat so that we can better understand what constitutes a healthy diet.”
In addition to Juraschek, coauthors include Allison W. Peng, BS, Lawrence J. Appel, MD, MPH, Noel T. Mueller, PHD, Olive Tang, AB, and Edgar R. Miller III, MD, PhD – all of The Johns Hopkins University School of Medicine, The Johns Hopkins Bloomberg School of Public Health, and the Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland.
This work was supported by the National Heart, Lung, and Blood Institute, Grant/Award Number: U01-HL57173, U01-HL57114, U01-HL57190, U01-HL57139,K08 HL03857-01 and U01-HL57156; General Clinical Research Center Program of the National Center for Research Resources, Grant/Award Number: M01-RR02635 and M01-RR00722; NIH/NHLBI, Grant/Award Number: K23HL135273, R21HL144876 and K01HL141589.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit http://www.
Related Journal Article